BDTX
Black Diamond Therapeutics, Inc.
An oncology drug developer, Black Diamond Therapeutics makes small-molecule medicines that treat whole 'families' of cancer-causing mutations with a single therapy, rather than one mutation at a time. Its lead experimental drug, BDTX-1535, can cross the blood-brain barrier to reach hard-to-treat brain tumors like glioblastoma. Co-founded in 2016 by scientists David Epstein and Elizabeth Buck, the company began as ASET Therapeutics before taking the Black Diamond name — a rebrand with no public origin story.
CUSIP: 09203E105HealthcareUS1 holder
Total Value
$1.70M
Total Shares
70.0K
Net Share Change
0
Activity
No changes
Investor
Value
Shares
Weight
Change
